Summary
Six healthy controls and 13 patients with Parkinson’s disease in different disability stages were studied with high resolution SPET using [123I]β-CIT-FP. The caudatusto-cerebellum and putamen-to-cerebellum ratios were calculated at 3.5 hours after injection. Patients had the significantly lower ratio than that of the controls in the putamen (3.0 ± 1.0 vs. 4.7 ± 0.4 ) and in the caudatus (3.5 ± 1.1 vs. 4.9 ± 0.5), respectively. There was a significant negative correlation between the ratio and the Hoehn and Yahr stage in the putamen (r = −0.74) and in the caudatus(r = −0.80). Reduced striatal uptake demonstrates the loss of presynaptic nerve endings in the striatum of the patients with Parkinson’s disease.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson’s diseased striatum. Synapse 1991; 9: 43–49.
Brücke T, Kornhuber J, Angelberger P, et al. SPECT imaging of dopamine and serotonin transporters with [123I]ß-CIT. Binding kinetics in the human brain. J Neural Transm [Gen Sect] 1993; 94: 137–146.
Rinne JO, Laihinen A, Ndgren K, et al. PET examination of the monoamine transporter with [11C]13-CIT and [11C]ß-CFT in early Parkinson’s disease. Synapse 1995; 21: 97–103.
Kuikka JT, Tiihonen J, Bergström KA, et al. Imaging of serotonin and dopamine transporters in the living human brain. Eur J Nucl Med 1995; 22: 346–350.
Kuikka JT, Bergstrom KA, Ahonen A, et al. Comparison of iodine-123 labelled 4carbomethoxy-313-(4-iodophenyl)tropane and 213-carbomethoxy-313-(4-iodophenyl)-N-(3fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 1995; 22: 356–360.
Kuikka JT, Akerman K, Bergstrom KA, et al. Iodine-123 labelled N-(2-fluoroethyl)-2ßcarbomethoxy-313-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain. Eur J Nucl Med 1995; 22: 682–686.
Hoehn MD, Yahr MM. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–442.
Rinne JO, Kuikka JT, Bergstrom KA, Rinne UK. Striatal dopamine transporter in different disability stages of Parkinson’s disease studied with [123I]13-CIT SPECT. Parkinsonism and Related Disorders 1995; 1: 47–52.
Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiat 1986; 49: 853–860.
Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]ß-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol 1995; 38: 589–598.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Basel AG
About this chapter
Cite this chapter
Kuikka, J.T., Rinne, J.O., Bergström, K.A., Kilpeläinen, H., Lehtovirta, M., Rinne, U.K. (1997). Striatal Dopamine Transporter in Parkinson’s Disease Studied with [123I]β-CIT-FP SPET. In: Bergmann, H., Kroiss, A., Sinzinger, H. (eds) Radioactive Isotopes in Clinical Medicine and Research. Advances in Pharmacological Sciences. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-7772-5_19
Download citation
DOI: https://doi.org/10.1007/978-3-0348-7772-5_19
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-7774-9
Online ISBN: 978-3-0348-7772-5
eBook Packages: Springer Book Archive